Next Article in Journal
Antitrypanosomal and Cytotoxic Activities of 22-Hydroxyclerosterol, a New Sterol from Allexis cauliflora (Violaceae)
Previous Article in Journal
Preparation and In Vivo Evaluation of Indomethacin Loaded True Nanoemulsions
Article Menu

Article Versions

Export Article

Scientia Pharmaceutica is published by MDPI from Volume 84 Issue 3 (2016). Articles in this Issue were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence. Articles are hosted by MDPI on as a courtesy and upon agreement with Austrian Pharmaceutical Society (Österreichische Pharmazeutische Gesellschaft, ÖPhG).
Open AccessArticle
Sci. Pharm. 2011, 79(1), 123-136; (registering DOI)

Formulation and Bioequivalence of Two Valsartan Tablets After a Single Oral Administration

Author to whom correspondence should be addressed.
Received: 1 September 2010 / Accepted: 18 November 2010 / Published: 20 November 2010
PDF [228 KB, uploaded 26 September 2016]


The aim of this study is to assess the quality of Valzan® tablet (160 mg, valsartan immediate release test formulation) by comparing its pharmacokinetic parameters with Diovan® tablet (160 mg, valsartan reference formulation). Valzan® tablets were prepared according to a dry granulation method (roll compaction). To assess the bioequivalence of Valzan® tablets a randomized, two-way, crossover, bioequivalence study was performed in 24 healthy male volunteers. The selected volunteers were divided into two groups of 12 subjects. One group was treated with the reference formulation (Diovan®) and the other one with the generic Valzan®, with a cross-over after the drug washout period of 14 days. Blood samples were collected at fixed time intervals and valsartan concentrations were determined by a validated HPLC assay method. The pharmacokinetic parameters AUC0–48, AUC0–∞, Cmax, Tmax, Ke and T1/2 were determined for both the tablets and were compared statistically to evaluate the bioequivalence between the two brands of valsartan, using the statistical model recommended by the FDA. The analysis of variance (ANOVA) did not show any significant difference between the two formulations and 90% confidence intervals (CI) fell within the acceptable range for bioequivalence. Based on this statistical evaluation it was concluded that the test tablets (Valzan®) is well formulated, since it exhibits pharmacokinetic profile comparable to the reference brand Diovan®.
Keywords: Valsartan; Formulation; Bioequivalence; Immediate Release; HPLC; Diovan®; Valzan® Valsartan; Formulation; Bioequivalence; Immediate Release; HPLC; Diovan®; Valzan®
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

ZAID, A.N.; CORTESI, R.; QADDOMI, A.; KHAMMASH, S. Formulation and Bioequivalence of Two Valsartan Tablets After a Single Oral Administration. Sci. Pharm. 2011, 79, 123-136.

Show more citation formats Show less citations formats

Article Metrics

Article Access Statistics



[Return to top]
Sci. Pharm. EISSN 2218-0532 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top